Committee for Veterinary Medicinal Products
This article was originally published in SRA
Highlights of the January 2004 meeting
You may also be interested in...
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.
Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.